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Autism is a spectrum of neurodevelopmental disorders with a primarily genetic etiology exhibiting deficits in (1)
development of language and (2) social relationships and (3) patterns of repetitive, restricted behaviors or interests
and resistance to change. Elevated platelet serotonin (5-HT) in 20%–25% of cases and efficacy of selective 5-HT
reuptake inhibitors (SSRIs) in treating anxiety, depression, and repetitive behaviors points to the 5-HT transporter
(5-HTT; SERT) as a strong candidate gene. Association studies involving the functional insertion/deletion poly-
morphism in the promoter (5-HTTLPR) and a polymorphism in intron 2 are inconclusive, possibly because of
phenotypic heterogeneity. Nonetheless, mounting evidence for genetic linkage of autism to the chromosome 17q11.2
region that harbors the SERT locus (SLC6A4) supports a genetic effect at or near this gene. We confirm recent
reports of sex-biased genetic effects in 17q by showing highly significant linkage driven by families with only affected
males. Association with common alleles fails to explain observed linkage; therefore, we hypothesized that preferential
transmission of multiple alleles does explain it. From 120 families, most contributing to linkage at 17q11.2, we
found four coding substitutions at highly conserved positions and 15 other variants in 5′ noncoding and other
intronic regions transmitted in families exhibiting increased rigid-compulsive behaviors. In the aggregate, these
variants show significant linkage to and association with autism. Our data provide strong support for a collection
of multiple, often rare, alleles at SLC6A4 as imposing risk of autism.
Introduction
In 1943, Leo Kanner published a series of 11 case reports
of children with a condition he termed “infantile autism”
or “autistic disturbances of affective contact” (Kanner
1943). Autism (MIM 209850) is now recognized as a
spectrum of phenotypes that spans a range of clinical
severity but fundamentally represents deficits in three
domains: (1) development and use of language, (2) de-
velopment of social relationships and interactions with
family and peers, and (3) patterns of repetitive behaviors,
restricted interests and activities, and a strong desire to
maintain “sameness” in environment and daily routines
(reviewed by Folstein and Rosen-Sheidley [2001]). Phar-
macotherapies include antipsychotic medications for dis-
ruptive and aggressive behaviors and selective serotonin-
reuptake inhibitors (SSRIs) for treatment of anxiety, de-
pression, and repetitive behaviors (Cook and Leventhal
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1996; Hollander et al. 2005). Of interest regarding the
partial efficacy of SSRIs are findings of elevated levels
of platelet serotonin (5-hydroxytryptamine [5-HT]) in
∼20%–25% of affected individuals (Schain and Freed-
man 1961) and correlation with levels in first-degree
relatives (Cook et al. 1993). Other findings supporting
5-HT involvement in autism are reviewed elsewhere
(Cook and Leventhal 1996; Veenstra-VanderWeele et al.
2000).
Since the first twin study of autism by Folstein and
Rutter in 1977 (Folstein and Rutter 1977), evidence has
mounted to support a predominantly genetic etiology of
autism (reviewed by Folstein and Rosen-Sheidley [2001]).
The prevalence of narrowly defined autism is ∼1/1,000
(Chakrabarti and Fombonne 2001), and inclusion of the
broader spectrum increases this rate to ∼1/300–1/500
(Fombonne 2003; Yeargin-Allsopp et al. 2003). Males
are affected more often, with a male:female ratio of
4:1. Twin data show that MZ twins have an average
concordance of ∼60%–70% for classic autism and up
to 90% when milder language and social deficits seen
in the broader phenotype are considered. This contrasts
with DZ twin concordance rates, shown to be 0%–
10%, depending on the study. Sibling-recurrence risk in
narrowly defined autism is ∼6%–8% (Jones and Szat-
mari 1988; Ritvo et al. 1989). Modeling the above data
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Table 1
Autism Family Samples for Linkage and Association Studies
SAMPLE
NO. OF FAMILIES
Multiplex Trio
Grand
TotalMO FC Total MO FC Total
AGRE 156 111 267 11 5 16 283
Tufts/Vanderbilt University 46 28 74 22 5 27 101
Total 202 139 341 33 10 43 384
has led to estimates of ∼5–15 genes that contribute to
genetic risk, possibly involving epistasis (Pickles et al.
1995), and locus heterogeneity (Risch et al. 1999). The
data may best be explained by oligogenic inheritance,
with different families possessing varying constellations
of risk alleles (Folstein and Rosen-Sheidley 2001). A
genetic-heterogeneity framework has important impli-
cations for the clinical variability observed in autism, in
that specific risk loci, or distinct alleles at a given locus,
are likely to influence the phenotype differently.
Several groups have undertaken family-based genetic
studies to (1) identify regions of the genome commonly
inherited by affected family members in multiplex-fami-
ly samples (i.e., genomic linkage screens) and/or (2) test-
specific loci for evidence of common alleles that confer
genetic risk on the basis of tests of allelic association
(reviewed by Folstein and Rosen-Sheidley [2001] and
Veenstra-VanderWeele et al. [2004]). Chromosomal in-
tervals identified in linkage studies with use of either a
categorical diagnosis or indexing on specific traits in-
clude 7q, 2q, and 17q (International Molecular Genetic
Study of Autism Consortium [IMGSAC] 1998, 2001a,
2001b; Ashley-Koch et al. 1999; Collaborative Linkage
Study of Autism (CLSA) et al. 1999; Philippe et al. 1999;
Risch et al. 1999; Auranen et al. 2000; Buxbaum et al.
2001, 2004; CLSA 2001; Liu et al. 2001; Shao et al.
2002a, 2002b; Yonan et al. 2003; McCauley et al. 2004,
2005; Stone et al. 2004; Cantor et al. 2005). For 17q,
second-stage genomic screens with use of different sam-
ples (IMGSAC 2001a; Yonan et al. 2003) detected highly
suggestive or significant linkage at or near the serotonin
transporter (SERT) locus (SLC6A4 [MIM 182138]) and
evidence of a sex-restricted pattern of genetic effects
(Stone et al. 2004). Our own reports of linkage to this
region, with use of family data sets that contain partial
overlap with the Autism Genetics Resource Exchange
(AGRE) sample (Yonan et al. 2003), lend further sup-
port to involvement of this region (McCauley et al. 2004,
2005).
Studies of allelic association at SLC6A4 with autism
have focused primarily on a functional, insertion-deletion
polymorphism in the promoter (5-HTTLPR) or a vari-
able number tandem repeat (VNTR) marker in intron 2.
Results of these studies are inconsistent, with associations
shown either to the short (S) or long (L) alleles or absent
association (Cook et al. 1997; Klauck et al. 1997; Maes-
trini et al. 1999; Persico et al. 2000; Tordjman et al. 2001;
Yirmiya et al. 2001). Four studies have reported more-
comprehensive analyses of common alleles and haplo-
types that span the locus, including multiple SNPs (Kim
et al. 2002; Conroy et al. 2004; McCauley et al. 2004;
Devlin et al., in press). These studies find at least nominal
association of the S allele at 5-HTTLPR and other mark-
ers or haplotypes. Our study of multiplex families (Mc-
Cauley et al. 2004) also showed very suggestive linkage
that cannot be explained by the modest association of
HTTLPR and rs140700 at SLC6A4. The two possible
explanations for these results are (1) that SLC6A4 is not
the risk locus accounting for linkage or (2) that multiple
different alleles at SLC6A4 contribute to genetic risk in-
dependently. We report further investigation of chromo-
some 17 linkage in families with autism and an in-depth
analysis of the SLC6A4 gene, testing the hypothesis that
allelic heterogeneity may account for the genetic liability
to autism. Using a large sample of multiplex families, we
find that SLC6A4 exhibits strong evidence of linkage to
autism, driven by allele-sharing in males. We find multiple
coding and noncoding variants preferentially transmit-
ted to affected individuals, and we identify significant
correlations with increased rigid-compulsive behaviors,
which indicates that SLC6A4 is a likely susceptibility lo-
cus for autism, where allelic heterogeneity supports dis-
ease risk.
Subjects and Methods
Sample and Genetic Analyses
The sample for the present study consisted of 73 fami-
lies recruited from the Tufts-Vanderbilt Consortium and
267 from the AGRE Consortium (table 1). The demo-
graphics of these populations have been reported else-
where (Yonan et al. 2003; McCauley et al. 2005) as have
diagnostic inclusion and exclusion criteria for linkage
analysis (McCauley et al. 2005). Families were selected
on the basis of the presence of a single proband who
met full Autism Diagnostic Interview (ADI) criteria for
autism and a second sibling who received the diagnosis
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Table 2
SLC6A4 SNP Marker Information
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
of autism or presented on the broader spectrum. In the
current report, we further examined linkage in a larger
sample of 341 families with at least two affected chil-
dren; for association studies and screening for known
variants (e.g., Gly56Ala), we included an additional 43
trios (proband and both parents). As reported elsewhere
(McCauley et al. 2005), Tufts/Vanderbilt families were
genotyped at deCODE by use of the deCODE 500 marker
panel with an average intermarker spacing of ∼8 cM.
Two-point and multipoint heterogeneity LOD (HLOD)
scores for individual and combined samples, respectively,
were calculated with Allegro, under both dominant and
recessive models (Gudbjartsson et al. 2000). Disease-
allele frequencies were estimated to be 0.01 and 0.1 for
dominant and recessive models, respectively. Phenotypic
status was considered only for affected individuals, and
other family members were designated as having an un-
known phenotypic status. Nonparametric allele-sharing
LOD* values were calculated using affected relative pair
data that was based on an exponential model with use
of the Spairs scoring function, as recommended by McPeek
(1999). Nonparametric linkage (NPL) scores and cor-
responding P values were also calculated with Allegro.
The position of chromosome 17 markers is based on the
deCODE genetic map (Kong et al. 2002).
Association tests of 5-HTTLPR and rs140700 were
performed using the pedigree disequilibrium test (PDT)
statistic (Martin et al. 2000), a variant of the transmis-
sion/disequilibrium test (TDT), developed for use with
general pedigrees. Genotype analysis of these markers has
been reported elsewhere (McCauley et al. 2004). Other
tests of association or comparison of allele frequencies
involved generation of a x2 statistic and corresponding
P values with use of standard 2#2 contingency tables.
Comparison of male:female affection for autism in the
presence of Gly56Ala alleles was performed using Fisher’s
exact test. Comparison of ADI-derived variable cluster
scores was performed using the T test—with incorpora-
tion of subject numbers, means, and standard deviations
for the overall data set and either (1) individuals within
a given family or (2) family means across multiple fami-
lies—to evaluate the significance of score differences. Sig-
nificance is reported as two-tailed P values. Approval
for these studies was granted by the respective institu-
tional review boards at Tufts University School of Medi-
cine/New England Medical Center and Vanderbilt Uni-
versity Medical Center. All studies were performed with
the informed consent of the families participating in the
research.
Variant Discovery
Known but rare SLC6A4 coding variants reported in
previous studies (Cargill et al. 1999; Glatt et al. 2001;
Hahn and Blakely 2002; Ozaki et al. 2003) were screened
in 327 multiplex families and 57 parent-child trios by use
of TaqMan allelic discrimination assays (table 2). When
possible, variants were assayed within exons to permit
inclusion of in vitro mutagenized plasmid cDNA samples
either alone or mixed with wild-type cDNAs, to provide
homozygous and heterozygous controls, respectively.
ABI TaqMan (Holloway et al. 1999) reactions were per-
formed in a 5-ml volume in accordance with manufac-
turer’s recommendations (Applied Biosystems). Cycling
conditions included an initial denaturation at 95C for
10 min, followed by 50 cycles of 92C for 15 s and 60C
for 1 min. Samples were analyzed using an ABI 7900HT
Sequence Detection System.
Screening for unknown variants involved arbitrary
selection of one affected individual from each of 120
families, ranked by family-specific nonparametric LOD*
scores from the overall 341-family data set. Screening
of PCR products for all exons was performed on the
first 24 samples, with temperature-gradient capillary elec-
trophoresis (TGCE) (Li et al. 2002), on a 96-capillary
Reveal system, in accordance with manufacturer’s recom-
mendations (Spectrumedix). Putative variants detected
by TGCE were confirmed by direct sequencing of PCR
product by use of ABI dye terminators in the Center for
Molecular Neuroscience Neurogenomics Core. The pro-
moter for the initial 24 individuals and both exons and
the promoter for samples from one proband from each
of the remaining 96 (of 120) families were analyzed for
variation by double-stranded direct sequencing of PCR
products with use of ABI dye terminator chemistry. ABI
electropherogram data obtained from Vanderbilt Cores
or from Polymorphic DNA Technologies were imported
and were analyzed for variation with the Phred/Phrap/
Consed and PolyPhred suite of sequence analysis tools
(Nickerson et al. 1997, 2001; Gordon et al. 2001). Vari-
ant confirmation and segregation of rare variants were
determined by sequencing available family members and
the original proband in the same manner. Location of
variation within the gene was documented in table 3
with nomenclature described by den Dunnen and An-
tonarakis (2001).
Functional Analysis of Gly56Ala Activity
and Regulation
Epstein-Barr virus (EBV)–transformed lymphocyte cell
lines from AGRE or Tufts/Vanderbilt families with au-
tism who carried either the Gly56 or 56Ala allele were
obtained from the National Institute of Mental Health
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Table 3
TD of Multiple Coding and Noncoding Alleles at SLC6A4
LOCATION AND
DBSNP NUMBER POSITIONa PROTEIN
NO. OF
FAMILIES
NO. OF TRANSMISSIONS TO
NO.
OF
NT
NO. OF AUTISTIC
All Affected
Individualsb All but Probandc Males Females
Exon 1b:
ss38318598 c.147CrA 5′ UTR 2 4 2 1 3 1
Exon 2:
rs6355 c.462GrC Gly56Alad 7 15 8 5 11 4
Exon 9:
ss38318599 c.1568ArC Ile425Leu 1 2 1 0 2 0
Exon 10:
ss38318600 c.1688TrC Phe465Leu 1 2 1 1 1 1
Exon 12:
ss38318601 c.1943GrC Leu550Val 1 2 1 0 2 0
Exon 13:
rs6352 c.2110ArC Lys605Asn 1 0 0 2 0 0
Exon 14:
rs13306796 c.2516ArG 3′ UTR 1 2 1 0 2 0
Promoter:
ss38318589 g.15622GrA NA 1 1 0 1 1 0
rs2020932 g.14519ArT NA 3 8 5 0 6 0
ss38318590 g.14289ArC NA 1e 1 0 1 1 0
rs25533 g.13912TrC NA 1 4 3 0 2 0
ss38318591 g.13754CrT NA (1)f (1) (0) (1) (1) (0)
Intron 1a:
ss38318592 IVS1a20CrT NA 1 1 0 0 1 0
ss38318593 IVS1a133GrA NA 1 1 0 0 1 0
hcv11414117 IVS1a47GrC NA 5 10 5 2 8 2
hcv11414114 IVS1a25GrA NA 4 9 5 0 7 2
Intron 1b:
ss38318594 IVS1b28GrA Gly56Alag 3 NA NA NA NA NA
Intron 6:
ss38318595 IVS644GrC NA 1 2 1 0 2 0
Intron 7:
ss38318596 IVS783CrT NA 4 9 5 0 9 2
Intron 8:
ss38318597 IVS833CrT NA 2 4 2 0 4 0
Total 31 76 40 12 63 12
NOTE.—NApnot applicable.
a Changes in the cDNA are indicated relative to the GenBank SLC6A4 reference sequence (accession number NM_001045); genomic
variants are designated by 1 corresponding to the initiating ATG or position within an intron.
b Transmissions to all affected individuals, including the proband in whom the variant was first identified ( ; ;2T:NTp 76:12 x p 26.82
1 df; ).7Pp 2.2# 10
c Transmissions excluding the screened proband in whom the variant was initially identified ( ; ; 1 df;2T:NTp 39:12 x p 8.13 Pp
)..0042
d Four 56Ala NTs derive from two heterozygous couples transmitting only one 56Ala allele to affected children.
e Redundant transmissions are not counted toward total transmissions.
f Family does not contribute to linkage; corresponding counts are not included in the totals.
g IVS1b28GrA lies on the Gly56Ala allele; therefore, to avoid redundancy, transmission was not considered.
(NIMH) Center for Collaborative Genetic Studies on
Mental Disorders repository. Lymphocytes were cul-
tured in suspension in RPMI 1640 medium (supple-
mented with 15% fetal bovine serum, 2 mM L-gluta-
mine, 100 units/ml penicillin, and 100 mg/ml strepto-
mycin) at 37C in a humidified incubator at 5% CO2
prior to assay. Lymphocytes were pelleted at 1,500 rpm
for 5 min and were washed with Krebs-Ringers-HEPES
(KRH) assay buffer. A total of cells in triplicate61# 10
were prewarmed (37C) in a shaking water bath (10 min)
in 12#75 polypropylene tubes in KRH buffer that con-
tained 100 mM pargyline and 100 mM ascorbic acid.
After a 5-min incubation with [3H]5-HT (20 nM) at
37C, uptake assays were terminated by immersion on
ice, and uptake in pelleted, 1% SDS-extracted cells was
quantitated by scintillation spectrometry. Specific 5-HT
uptake was determined by subtracting the amount of
[3H]5-HT accumulated in the presence of 10 mM pa-
roxetine (SmithKline Beecham). [3H]L-glutamate trans-
port assays were conducted as described for [3H]5-HT,
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except with use of 100 nM substrate and definition of
nonspecific uptake, with parallel accumulation acquired
at 4C.
Results
Linkage
On the basis of our initial linkage results (McCauley
et al. 2004) and other reports of linkage to 17q (IMGSAC
2001a; Yonan et al. 2003), we substantially increased
our sample of 73 Tufts/Vanderbilt and 85 AGRE families
through acquisition from the NIMH repository; we reas-
sessed evidence of linkage in the larger sample that con-
tained 182 additional AGRE families. We found striking
linkage in an overall data set of 341 multiplex families,
with a peak recessive HLOD (HLODREC) score of 5.8
(fig. 1A) at two adjacent markers at ∼53 cM (D17S1800
[∼1.4 Mb from SLC6A4] and D17S1294 [∼150 kb from
SLC6A4]). Results from all parametric and NPL analy-
ses are detailed in table 4. Influenced by two recent re-
ports (Stone et al. 2004; Weiss et al. 2005), we incor-
porated a sex-specific approach in our linkage analysis
of chromosome 17. We queried for male-specific effects
by splitting the data set into (1) families containing only
affected males (MO) and (2) the remaining female-con-
taining (FC) families, similar to the approach of Stone
and colleagues (2004). Linkage increased substantially
in the MO sample ( ; ), withHLOD p 8.0 np 202REC
negligible contribution from the 138 remaining FC fami-
lies. The magnitude of linkage overall and in the MO
families, extraordinary for a complex behavioral dis-
order, encouraged us to pursue more-detailed studies to
identify autism-associated alleles within SLC6A4.
Association
Initially, we tested for evidence of allelic association
using the two markers (5-HTTLPR and the intron 5 SNP
rs140700) that previously demonstrated modest associa-
tion in a smaller sample (McCauley et al. 2004). In a
sample of 384 combined multiplex and trio families, we
detected evidence of allelic association with autism (i.e.,
) only at thetransmissions [T] 1 nontransmissions [NT]
intron 5 marker rs140700 (minor allele T:NTp 93:124;
; ). However, when MO and FC sub-2x p 4.47 Pp .03
sets were examined separately, modest association of the
S allele of 5-HTTLPR was detected in the MO data set
( families; ; ;2np 235 T:NTp 362:314 x p 4.90 Pp
) as well as persistent undertransmission of the minor.03
allele at rs140700 ( ; ;2T:NTp 47:76 x p 6.84 Pp
), whereas no association or trend toward associa-.009
tion was seen in the 149 FC families (HTTLPR-S: T:NT
p 223:231, , ; rs140700:2x p 0.07 Pp .79 T:NTp
, , ). The association in MO246:48 x p 0.021 Pp .88
families is consistent with previous results (McCauley et
al. 2004) and the male bias in linkage (Stone et al. 2004),
but it fails to explain the highly significant linkage in
MO families shown above.
Allelic Heterogeneity at SLC6A4
Since common alleles across the SLC6A4 locus do not
explain the observed linkage, we considered the hypothe-
sis that multiple, possibly rare, SLC6A4 risk alleles exist
and confer risk of autism. We tested our hypothesis using
two parallel strategies. We first screened all families for
known rare coding variants to determine if one or more
is present at elevated frequency in our autism sample
and, by inference, is potentially related to disease risk.
Our second approach involved (1) selecting unrelated
probands from the multiplex families that contribute
most to linkage and, at minimum, have a positive LOD
score at the linkage peak and (2) screening their SLC6A4
exons and promoter sequences for novel variants. In our
combined sample of 384 multiplex families and parent-
child trios, we screened for known nonsynonymous vari-
ants using TaqMan allelic discrimination assays. We de-
tected multiple individuals who carried one or two copies
of the 56Ala-encoding allele and a single subject hetero-
zygous for an allele encoding the nonsynonymous vari-
ant Lys605Asn.
Detailed analysis of families with the Gly56Ala sub-
stitution reveal its presence in both “linked” (positive
LOD scores) and “unlinked” multiplex families and
trios. Within the 120 families with the highest family-
specific LOD scores, we found the 56Ala allele present
on 11 (2.3%) of 480 independent chromosomes. Three
homozygous 56Ala subjects were identified in these fami-
lies. In contrast, Glatt et al. (2001) reported the 56Ala
variant occurred on only 4 of 900 chromosomes in the
only large nonclinical comparison sample described, with
a minor-allele frequency (MAF) of 0.44% and no ho-
mozygous subjects. In our remaining families with au-
tism, we found a lower frequency of the 56Ala allele,
with 12 (1.1%) of 1,056 chromosomes harboring the
variant; no homozygotes were identified for this group.
An alternative comparison comes from our screening of
a predominantly white population ascertained for Axis
I Mood Disorders. Here, we identified 3 (1.1%) of 272
chromosomes with 56Ala alleles (J. R. Field, H.C.P.,
R.D.B., E. Sanders-Bush, and R. C. Shelton, unpublished
findings).
A parallel strategy involved screening the promoter,
exons, and flanking sequence of unrelated probands from,
initially, 24 families who most contributed to linkage in
this region, on the basis of ranking for family-specific
LOD scores. TGCE followed by direct sequencing of
PCR products comprised the initial effort, and one pro-
band sample from each of the remaining 96 (of 120)
families was subjected to direct sequencing of PCR prod-
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Figure 1 Male-biased linkage of autism and novel coding variants at the 17q11.2 SLC6A4 locus. A, Male-biased linkage of autism to
17q11.2. Multipoint linkage analysis on chromosome 17 is shown for the overall 341-family data set (black line), 202 MO families (blue line),
or the remaining 138 FC families (red line). HLOD scores were calculated under a recessive model and were plotted as a function of marker
position in centimorgans (cM) along chromosome 17. B–D, Sequence detection of novel nonsynonymous SLC6A4 variants in families with
autism. Sequence-based detection is shown for each of the three novel coding variants, with corresponding pedigrees. B, Ile425Leu. C, Phe465Leu.
D, Leu550Val. Blackened circles or squares reflect individuals with an autism diagnosis, unblackened circles or squares reflect individuals without
autism, and allele carriers without autism are indicated by small blackened circles or squares within the larger pedigree symbol. Electropherogram
data is shown in either sense (B) or antisense (A and C) orientations, with corresponding coding sequence. Antisense sequences (A and C)
indicate the reversed orientation of amino acid codons, represented by lines across each three-base sequence. Variant amino acids are shown
in red, and corresponding heterozygous sequence changes are indicated by an arrow. Individual numbers in the respective pedigrees correspond
to numbers within each of the sequence frames. E, Schematic representation of the 5-HT transporter. Amino acid substitutions are indicated
by location within transmembrane or cytoplasmic domains. F, Dosage-dependent elevated 5-HT transporter activity of Ala56-encoded hSERT
in native lymphoblastoid cells. Lymphocytes genotype-matched at 5-HTTLPR (L/L) and the intron 2 VNTR (10/10) and bearing Gly/Gly–, Gly/
Ala–, or Ala/Ala–encoding genotypes at residue 56 were assayed for [3H]5-HT transport activity, as described (see the “Subjects and Methods”
section). Three independent experiments were performed in triplicate for each line, and the combined basal uptake data were plotted.
ucts. In addition to the independent identification of one
56Ala homozygote, two novel coding variants (Ile425Leu
and Leu550Val) (fig. 1B and 1D) were detected in the
24 most-linked families ( allele frequency).4/48p 8.3%
In the remaining 96 families, several 56Ala alleles and
a Phe465Leu nonsynonymous substitution (fig. 1C) were
detected (table 3). All three coding substitutions occur
within transmembrane domains (fig. 1E) and are highly
conserved (fig. 2). The least conserved of the novel vari-
ants corresponds to residue Ile425, which is present
within all SERT proteins from human to Drosophila.
The other two nonsynonymous variants occur at resi-
dues conserved from human to Drosophila in all mon-
oamine transporters—including SERT, the norepineph-
rine transporter (NET), and the dopamine transporter
(DAT)—for which sequence was available.
To consider the genetic relevance of the coding vari-
ants to autism risk, we asked if these variants segregated
with disease in each family. Two of the three novel cod-
ing variants were transmitted to all affected individuals
(5 males and 1 female) in the three families (fig. 1B–1D).
One affected male did not inherit the paternally trans-
mitted Phe465Leu variant allele. The 425Leu allele ex-
hibited a particularly intriguing overall segregation pat-
tern (fig. 1B). This variant was maternally transmitted
to both affected sons. Three unaffected daughters also
inherited the allele, but two other unaffected siblings, one
male and one female, did not. When the clear sex bias
in linkage is considered, segregation of the 425Leu allele
in this family is consistent with but not proof of male-
biased genetic risk or elevated penetrance associated with
the allele. No unaffected siblings were present in the
other two families. The 56Ala allele was detected in
seven linked families, in which the T:NT was 15:5 (table
3). Of the five nontransmissions, four correspond to two
distinct instances in which both parents were carriers
(expected to occur in ∼1 of every 2,000 couples, under
the assumption of Hardy-Weinberg equilibrium [HWE]),
and offspring received only one Ala56 allele. The other
nontransmitted 56Ala allele was present in the mother
of the family that paternally transmitted the Phe465Leu
variant. Of the three homozygous individuals in the 120
linked/screened families, two were affected male off-
spring and one was a mother for whom medical history
information was unavailable but who transmitted the
allele to two affected male offspring. Analysis of the
unlinked multiplex and simplex families with a 1.1%
(12/1056) 56Ala frequency did not show bias in trans-
mission (data not shown). There was a significant effect
in a larger 643 multiplex/trio data set for autism in males
carrying one or two 56Ala alleles compared with females
(23:14 affected:unaffected males vs. 7:16 affected:un-
affected females; ).Pp .016
Clinical Correlations
To explore phenotypic correlates with the coding vari-
ants, we compared scores for trait subsets of autism that
were based on ADI-Revised (ADI-R)–derived variable
clusters (table 5) identified elsewhere from a principal-
components analysis of ADI-R items (Tadevosyan-Ley-
fer et al. 2003). These clusters reflect (1) language, (2)
social intent, (3) developmental milestones, (4) savant
skills, (5) rigid-compulsive, and (6) sensory-aversion as-
pects of the autism phenotype. There was a significant
increase in rigid-compulsive behaviors associated with
the novel variants ( ) (table 5), and the effectPp .0003
was most pronounced for the Ile425Leu and Leu550Val
families. The Ile425Leu substitution tracked with more-
severe language deficits ( ), although the broth-Pp .0031
ers harboring the allele were generally more affected
across most factor domains, with the exception of sen-
sory aversions. The Leu550Val and Phe465Leu variants
were associated with lesser impairment in language and
social-intent domains, significantly so for the Phe465Leu
variant ( and , respectively). TheP ! .0001 Pp .0021
Gly56Ala variant (heterozygous or homozygous) in the
linked families similarly demonstrated a significant as-
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Figure 2 ClustalW alignment of hSERT amino acid sequence
versus other species of SERT and other biogenic amine transporters.
The legend is available in its entirety in the online edition of The
American Journal of Human Genetics.
Table 4
Autism Linkage Data for Chromosome 17
FAMILY SAMPLE MARKER
POSITIONa
(cM)
HLOD
LOD* LOD* Pb NPL NPL PbDominant Recessive
Overall ( )np 340 D17S1800 53 4.98 5.44 5.82 71.59# 10 4.88 86.63# 10
MO ( )np 189 D17S1800 53 5.35 7.86 6.65 84.85# 10 5.18 81.64# 10
FC ( )np 138 D17S1800 53 .4 .06 .46 .085 2.21 .073
a Position on the deCODE chromosome 17 genetic map.
b P values are nominal and are not corrected.
sociation with more severe rigid-compulsive behaviors
( ). When all linked families with individualsPp .0085
carrying a coding variant were considered together, the
significance in elevated severity of rigid-compulsive be-
haviors increased ( ). No consistent pattern wasPp .0002
observed across all Gly56Ala families, regardless of sex,
for other ADI clusters; however, there appeared to be a
trend toward two subgroups. In one group, patients had
greater severity for rigid-compulsive and sensory-aver-
sion behaviors, with fewer impairments in language and
social domains. The second group did not show the sen-
sory-aversion finding but was more impaired in language
(table 5).
Functional Properties of Gly56Ala SERT
The presence of multiple homozygous 56Ala subjects
in our multiplex autism sample allowed evaluation of
the functional impact of a 56Ala substitution on SERT
activity and regulation by use of genotyped, EBV-trans-
formed lymphocytes, since SLC6A4 is natively expressed
in those cells (Khan et al. 1996; Lesch et al. 1996; Faraj
et al. 1997). Basal 5-HT transport activity was elevated
in Ala56-expressing cells (T test, ) compared withP ! .05
Gly56 homozygous, Gly56Ala heterozygous, or com-
bined Gly56 genotypes; significance remains after nor-
malization to L-glutamate transport activity and does not
segregate with the SLC6A4 genotype (fig. 3). To control
for potential confounding effects of variation in SLC6A4
gene expression and downstream basal 5-HT uptake as-
sociated with 5-HTTLPR and intron 2 VNTR geno-
types (Lesch et al. 1996; Ogilvie et al. 1996; MacKenzie
and Quinn 1999), we repeated studies with two cell lines
of each Gly56Ala genotype that carried identical 5-
HTTLPR (L/L) and intron 2 VNTR (10/10) genotypes.
Figure 1F demonstrates a 56Ala dosage-dependent effect
on basal 5-HT transport activity, with ∼75% increase
evident for the 56Ala homozygous lines as compared
with lines homozygous for 56Gly. In these cells, we also
demonstrated that the 56Ala allele is refractory to regu-
lation by acute application of activators of protein ki-
nase G (PKG) or p38 mitogen-activated protein kinase
(MAPK) (Miller and Hoffman 1994; Qian et al. 1997;
Ramamoorthy and Blakely 1999; Zhu et al. 2004, 2005;
Samuvel et al. 2005) (fig. 4A and 4B), which suggests
that intrinsic features of function unlikely to be attrib-
utable to a linked, noncoding variant are evident. We
recently described a similar loss of regulation despite
normal surface density for 56Ala cDNA transfected into
HeLa cells (Prasad et al., in press).
Association of Heterogeneous Alleles with Autism
To more completely evaluate the SLC6A4 locus for
novel alleles, we expanded our screen to cover proximal
promoter sequences and noncoding 5′ and 3′ exons. We
subsequently analyzed 31 families for allelic segregation
patterns for rare, noncoding variants discovered across
the locus. Variants were identified in the promoter, exon
1b, exon 14, and intronic sequences in the linked families
(table 3). Several variants are known polymorphisms with
existing database identifiers, although many are novel.
Other polymorphisms with modest-to-high MAF were
tested elsewhere for association and are not included in
table 3. Allelic segregation patterns reveal a stark pattern
of transmission disequilibrium (TD) when all variants are
combined for purposes of considering segregation. Re-
dundant allelic transmissions represented by two or more
SNPs were not counted more than once. TD was evident
from a T:NT count of 76:12, which represents a highly
significant deviation from the null hypothesis of no as-
sociation ; 1 df; ). There is2 7(x p 26.82 Pp 2.2# 10
an a priori expectation of transmission (or de novo se-
quence change) to index cases in whom variants were
originally detected. To reduce this bias, transmissions
to these individuals were excluded, yet segregation
remained significant ( ; ; 1 df;2T:NTp 40:12 x p 8.13
). Therefore, these multiple coding and non-Pp .0042
coding alleles persist in demonstrating a collective link-
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Figure 3 Altered basal 5-HT transport activity and regulation
associated with the Gly56Ala variant. The legend is available in its
entirety in the online edition of The American Journal of Human
Genetics.
Figure 4 SERT is refractory to regulation through PKG and p38
MAP kinase signaling pathways. A, SERT Ala56 lacks sensitivity to
8BrcGMP. Homozygous Ala56 cells ( /tube) were preincubated for610
various lengths of time at 37C, with 10 mM 8BrcGMP prior to [3H]5-
HT transport assays. B, SERT Ala56 lacks sensitivity to the p38 MAPK
activator anisomycin; 8BrcGMP effects on Gly56 SERT are completely
blocked by coincubation with the PKG inhibitor H8 (10 mM), whereas
the p38 MAPK inhibitor SB203580 (1 mM) prevented anisomycin stimu-
lation (data not shown). Data plotted represent mean data  SD
( ) for a single cell line of each genotype assayed in parallel.np 3
Findings were replicated with identical results in an additional line for
each genotype.
age to and allelic segregation with autism, despite failure
to identify association of common alleles (apart from
HTTLPR and rs140700) at SLC6A4 in these families.
Discussion
Two recent reports are notable for leveraging the sex
bias of disease affection in autism to define an analytical
framework that identified significant male-biased genetic
effects at 17q. The AGRE Consortium reported a ge-
nomewide analysis with use of sex (as presented here)
to stratify a 257-family data set (Stone et al. 2004), and
they have recently replicated evidence for male-biased
linkage to 17q (Cantor et al. 2005). They compared over-
all linkage with that of MO families and of FO fami-
lies. They found a significant effect at 17q11.2 near the
SLC6A4 locus (∼53 cM), with MO families showing an
empirically significant increase of linkage from a maxi-
mum LOD score (MLS) of 3.2 in the overall data set to
an MLS of 4.3 in the 148-family MO data set. Our analy-
ses, which include AGRE and Tufts/Vanderbilt families,
confirm these previous observations by the AGRE Con-
sortium yet show more-pronounced overall and male-
biased genetic effects at this locus. In the second report,
Weiss et al. (2005) showed significant association of
marker alleles at SLC6A4 and the 17q31 integrin b3
(ITGB3 [MIM 173470]) locus, with male-specific ge-
netic influences on 5-HT levels. ITGB3 was detected
earlier by Weiss et al. (2005) as a QTL for circulating
serotonin levels. Our own recently published genomic
linkage screen showed two adjacent linkage peaks on
proximal 17q (McCauley et al. 2005). Conditional link-
age analyses revealed locus- or peak-specific effects, which
supports the premise that both SLC6A4 at 53 cM and
another more telomeric locus (possibly ITGB3) contrib-
ute to genetic effects in this region. We speculate on the
basis of published linkage patterns—including the AGRE
replication study that showed linkage ( ) toMLSp 3.6
a more distal site in 17q21 (Cantor et al. 2005)—that
overall linkage in this region represents two loci, with
the likely stronger effect at SLC6A4.
We were struck by the extraordinary evidence of link-
age, given that common alleles and haplotypes fully
representing LD across the locus failed to explain the
linkage, as would be predicted under the “common dis-
ease-common allele” hypothesis. Given the above ob-
servations, we considered the alternative hypothesis that
allelic heterogeneity explained risk at SLC6A4. We have
discovered three novel highly conserved coding variants
in families that strongly contribute to linkage in this re-
gion. Two of the three novel coding variants (Ile425Leu
and Leu550Val), a 56Ala homozygous proband, and a
novel intron 6 SNP (IVS6-44GrC) were identified among
24 probands (8.3% allele frequency) from families with
the highest family-specific LOD scores. These two novel
alleles segregate to all affected individuals in their re-
spective families and thus are associated with disease.
These findings spawned further discovery efforts that
led to the identification of 13 novel SNPs, including the
Phe465Leu nonsynonymous variant. The family with
this latter variant is of interest because the mother car-
ried but did not transmit the 56Ala allele. She did trans-
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mit a rare genomic variant (hCV11414114) (table 3) to
all affected children. The study by Glatt and colleagues
(2001) did not detect the three novel coding alleles in
the 450 individuals (900 chromosomes) sequenced; this
indicates that these alleles are rare and have a frequency
of !1/900, or !0.11%.
Cross-species conservation of novel coding-variant
residues and their identification in linked families sug-
gests an increased likelihood of altered functionality for
the variant transporter, although future study will be
required to fully elaborate this premise. All three novel
substitutions occur within transmembrane domains (fig.
1E), and the 425Leu allele affects the identical residue
and nucleotide—as does the Ile425Val mutant in the
pedigrees described by Ozaki and colleagues (2003)—
that segregates Asperger syndrome (MIM 608638), ob-
sessive-compulsive disorder (OCD [MIM 164230]), and
other psychiatric phenotypes. The Ile425Leu variant
does, therefore, have an a priori increased likelihood of
functional effect that is based on prior precedent from
disease association and subsequent functional charac-
terization of the Ile425Val substitution showing ∼2-fold
elevated basal activity in transfection studies (Kilic et
al. 2003; Prasad et al., in press).
The Gly56Ala substitution shows a very suggestive
increase of MAF to 2.3% in the 120 linked families,
compared with the 1.1% seen in the remaining families.
A 2.3% allele frequency represents a noticeable increase
over the single nonclinical reference study (Glatt et al.
2001), which shows 4 of 900 (0.44%) chromosomes
(and no homozygotes) carrying a 56Ala allele. HWE
would dictate a frequency of homozygous individuals
to be ∼1/2,000 in unrelated individuals (or ∼1/5,000 on
the basis of a 0.44% frequency in the Glatt et al. [2001]
comparison sample). Therefore, our finding of three ho-
mozygotes and two additional (unrelated) instances of
dual heterozygous couples is highly unlikely by chance
( ). The findings of (1) an apparent fivefold increaseP ≈ 0
in 56Ala allele frequency in the linked families, with a
trend toward overtransmission, (2) a substantial devia-
tion from HWE, and (3) a male-biased trend toward
autism affection in the presence of this allele compared
with females indicates a role for the 56Ala allele as a
genetic risk factor in autism. The infrequency of the allele,
however, makes this more difficult to quantitate. Larger
autism population studies are indicated.
Equally important are functional data that demon-
strate that the 56Ala SERT protein displays an elevated
basal activity and insensitivity to regulation through
PKG and p38 MAPK signaling pathways in a native cell
system. Importantly, down-regulation in response to pro-
tein kinase C–activating phorbol esters was equivalent
between Gly56 and Ala56 lines (data not shown). We
do not believe that PKG/p38 MAPK regulatory insen-
sitivity derives directly from altered basal activities, since
we have demonstrated transport regulation through these
pathways with other variants that differed up to 10-fold
in activity (Prasad et al., in press), although over-expres-
sion in transfected cells can blunt regulation (C.-B. Zhu
and R.D.B., unpublished findings). Elevated basal 5-HT
uptake is also not due to enhanced transcription, since
RealTime PCR analysis revealed equal SERT mRNA lev-
els in the Gly56 and Ala56 lines (data not shown). El-
evated basal activity of the Ala56-encoded transporter
is intriguing in light of a similar effect with 425Val-
encoded SERT in patients with Asperger syndrome and
OCD. Although altered regulation was not seen with
the Ile425Val mutation, the elevated basal transporter
activity may suggest a common functional mechanism
important in autism, OCD, and other phenotypes. It is
possible that prolonged expression of a variant lacking
regulation induces other compensatory changes that in-
fluence basal transporter activity. Regardless, these find-
ings suggest that Gly56Ala carriers may possess an in-
flexibility to regulatory stimuli that could thereby com-
promise appropriate demand-dependent modulation of
SERT surface expression and/or catalytic activity.
Phenotypically, the three novel variants and Gly56Ala
are significantly associated with increased rigid-compul-
sive behaviors. These include (1) stereotyped utterances,
(2) unusual preoccupations, (3) compulsions/rituals, (4)
resistance to trivial changes in the environment, and (5)
unusual attachment to objects (Tadevosyan-Leyfer et al.
2003). This is important for several reasons. Our pre-
vious study of linkage in a smaller sample demonstrated
a significant increase in linkage at ∼53 cM when the
same rigid-compulsive trait was used to stratify the data
set (McCauley et al. 2004). It is consistent with the
finding of Asperger syndrome, OCD, and other traits
in families segregating the functionally abnormal (Pra-
sad et al., in press) Ile425Val substitution (Ozaki et
al. 2003). Obsessive-compulsive–type traits and clinical
OCD are seen more frequently in families with autism
than in the general population (Bolton et al. 1998). Re-
petitive behaviors and associated anxiety in autism and
OCD are often effectively treated with SSRIs, targeting
the SERT protein (Hollander et al. 2005). Whereas
other phenotypic findings associated with specific vari-
ants were variable across families with all four variants,
increased severity for the rigid-compulsive domain was
a consistent finding for these variants. Given the mag-
nitude of the observed genetic effect, the possibility ex-
ists that our sample may be enriched by chance or se-
lection methods for phenotypic traits (or regional alleles)
that bias in favor of an effect at this locus.
The functionality of promoter and other noncoding
variants is unknown; however, the segregation of these
multiple variants in aggregate, in addition to the coding
variants, provides additional genetic evidence of an
allelic heterogeneity framework for disease risk involv-
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ing SLC6A4. Several previously documented variants
(rs2020932, hCV11414117, and hCV11414114) were
each found in multiple families. These heterogeneous
variants arose largely on independent haplotypic back-
grounds, which indicates that they are rare independent
events and are not the result of an effect of some com-
mon genetic background. The clustering of collectively
associated rare genomic variants in the promoter and
near the 5′ end of the gene raises the possibility of tran-
scriptional effects at SLC6A4. Intronic or noncoding
transcribed variants may, if they are risk factors with
biological relevance, affect transcription, transcript sta-
bility, or RNA splicing (Pagani and Baralle 2004). An
expression-based mechanism for potentially disease-re-
lated 5′ variants is consistent with association of the
HTTLPR marker, since the insertion/deletion variant
exhibits differential transcription. Even with a relatively
conservative analysis of transmission by eliminating the
subject from each family in whom the variant was dis-
covered, association data in the presence of linkage must
be interpreted cautiously. The analysis of transmissions
in families with an a priori expectation of variable allele-
sharing would inflate any measure of allelic association,
and the TDT analysis of multiplex families in this un-
usual context would yield a measure of linkage (Spiel-
man and Ewens 1996). Nevertheless, the context in
which these observations are made supports the signifi-
cance of association in the aggregate of these multiple
variants. The modest association at 5-HTTLPR and the
intron 5 SNP rs140700 in the current MO sample is
not only consistent with but is also supportive of this
proposed risk framework. Other common alleles are not
associated with autism, whereas the heterogeneous rare
alleles described in this report are. Thus, the most par-
simonious model involves multiple different risk alleles
(including 5-HTTLPR) that act in different families to
collectively account for the observed linkage.
The import of our data is summarized by the con-
stellation of findings, including (1) three novel highly
conserved coding variants, one of which affects a resi-
due (Ile425) with known phenotypic and functional rele-
vance; (2) the dysfunctional properties of SERT encoded
with the Gly56Ala substitution; (3) the stark deviation
from HWE and increased frequency in linked families;
(4) a phenotypic correlation between coding variants
and increased rigid-compulsive behaviors; and (5) the
aggregate association shown by heterogeneous promoter
5′ and intragenic noncoding variants. These data col-
lectively support the premise that SLC6A4 represents a
susceptibility locus for autism-spectrum disorders. Our
findings must be examined in larger independent autism
family populations with similar phenotypic representa-
tion to determine their ultimate significance. Given the
linkage reported at SLC6A4 by IMGSAC (as well as
AGRE) and incomplete screening in the current sample
(only one affected individual per family was screened
for exon and promoter variants), we suspect that ad-
ditional coding and noncoding variants will be discov-
ered at this locus. As they stand now, our findings pro-
vide compelling evidence that the SLC6A4 locus is a
bona fide autism-susceptibility gene, with variants pre-
disposing to rigid-compulsive traits.
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